Compare · GRAL vs ILMN
GRAL vs ILMN
Side-by-side comparison of GRAIL Inc. (GRAL) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRAL and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.56B, about 9.5x GRAL ($2.57B).
- ILMN has been more active in the news (21 items in the past 4 weeks vs 11 for GRAL).
- ILMN has more recent analyst coverage (25 ratings vs 12 for GRAL).
- Company
- GRAIL Inc.
- Illumina Inc.
- Price
- $59.97-9.94%
- $162.28-3.39%
- Market cap
- $2.57B
- $24.56B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 11
- 21
- Recent ratings
- 12
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest GRAL
- Chief Growth Officer Partridge Andrew John sold $91,070 worth of shares (1,491 units at $61.08), decreasing direct ownership by 0.90% to 163,738 units (SEC Form 4) (withholding obligation)
- Goldman initiated coverage on GRAIL with a new price target
- Chief Executive Officer Ofman Joshua J. was granted 31,055 shares, increasing direct ownership by 8% to 402,271 units (SEC Form 4)
- New insider Partridge Andrew John claimed ownership of 165,229 shares (SEC Form 3)
- Wolfe Research resumed coverage on GRAIL
- GRAIL Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
- GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
- GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Latest ILMN
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director King David P was granted 2,072 shares (SEC Form 4)